Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma

The impact of age on the clinical benefit of anti-PD1 immunotherapy in advanced melanoma patients has been evolving recently. Due to a reduced immune function in elderly patients, young patients with a robust immune system are theoretically expected to benefit more from the treatment approach. Howev...

Descripción completa

Detalles Bibliográficos
Autores principales: Machiraju, Devayani, Schäfer, Sarah, Hassel, Jessica C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707626/
https://www.ncbi.nlm.nih.gov/pubmed/34947849
http://dx.doi.org/10.3390/life11121318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707626/
https://www.ncbi.nlm.nih.gov/pubmed/34947849
http://dx.doi.org/10.3390/life11121318

Ejemplares similares